EBS
Price
$6.79
Change
+$0.02 (+0.30%)
Updated
Sep 25 closing price
Capitalization
347.12M
46 days until earnings call
Intraday BUY SELL Signals
MYLD
Price
$32.48
Change
+$0.13 (+0.40%)
Updated
Sep 25 closing price
Net Assets
52.29M
Intraday BUY SELL Signals
Interact to see
Advertisement

EBS vs MYLD

EBS vs MYLD Comparison Chart in %
View a ticker or compare two or three
VS
EBS vs. MYLD commentary
Sep 26, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EBS is a StrongBuy and MYLD is a Hold.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
EBS: Fundamental Ratings
EBS
OUTLOOK RATING
1..100
28
VALUATION
overvalued / fair valued / undervalued
1..100
46
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
55
P/E GROWTH RATING
1..100
5
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
EBSMYLD
RSI
ODDS (%)
Bearish Trend 2 days ago
85%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 1 day ago
79%
Momentum
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 1 day ago
74%
MACD
ODDS (%)
Bullish Trend 3 days ago
82%
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 1 day ago
73%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 1 day ago
71%
Advances
ODDS (%)
Bullish Trend 9 days ago
78%
Bullish Trend 12 days ago
85%
Declines
ODDS (%)
Bearish Trend 5 days ago
87%
Bearish Trend 2 days ago
70%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 1 day ago
74%
Aroon
ODDS (%)
Bullish Trend 2 days ago
86%
Bearish Trend 1 day ago
72%
COMPARISON
Comparison
Sep 26, 2026
Stock price -- (EBS: $6.79)
Brand notoriety:
Market capitalization --

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EBS’s FA Score shows that 1 FA rating(s) are green while .

  • EBS’s FA Score: 1 green, 4 red.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EBS’s TA Score shows that 6 TA indicator(s) are bullish.

  • EBS’s TA Score: 6 bullish, 4 bearish.

Price Growth

EBS (@Pharmaceuticals: Generic) experienced а -0.15% price change this weekfor the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +3.49%. For the same industry, the average monthly price growth was -6.14%, and the average quarterly price growth was +42.31%.

Reported Earning Dates

EBS is expected to report earnings on Nov 11, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (+3.49% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

View a ticker or compare two or three
EBS
Daily Signal:
Gain/Loss:
MYLD
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ZKIN2.340.54
+30.00%
ZK International Group Co Ltd
LBRT18.940.70
+3.84%
Liberty Energy
MLR54.040.20
+0.37%
Miller Industries
VIV11.60-0.09
-0.77%
Telefonica Brasil SA
AEMD6.28-0.49
-7.24%
Aethlon Medical Inc

EBS and

Correlation & Price change

A.I.dvisor indicates that over the last year, EBS has been loosely correlated with SIGA. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if EBS jumps, then SIGA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EBS
1D Price
Change %
EBS100%
+0.30%
SIGA - EBS
40%
Loosely correlated
+6.15%
COLL - EBS
40%
Loosely correlated
-0.49%
AMPH - EBS
37%
Loosely correlated
-0.53%
XERS - EBS
33%
Loosely correlated
+1.68%
VTRS - EBS
30%
Poorly correlated
+2.35%
More

MYLD and

Correlation & Price change

A.I.dvisor tells us that MYLD and EBS have been poorly correlated (+22% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MYLD and EBS's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MYLD
1D Price
Change %
MYLD100%
+0.39%
EBS - MYLD
22%
Poorly correlated
+0.30%
SBGI - MYLD
16%
Poorly correlated
+0.31%
GEF - MYLD
16%
Poorly correlated
-0.19%
INVA - MYLD
12%
Poorly correlated
+0.39%
LNC - MYLD
12%
Poorly correlated
+0.72%
More